Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DA 1241

Drug Profile

DA 1241

Alternative Names: DA-1241

Latest Information Update: 22 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dong-A ST
  • Developer Dong-A ST; NeuroBo Pharmaceuticals
  • Class Antihyperglycaemics; Hepatoprotectants; Small molecules
  • Mechanism of Action GPR119 protein agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Type 2 diabetes mellitus

Highest Development Phases

  • Phase II Non-alcoholic steatohepatitis
  • Phase I Type 2 diabetes mellitus

Most Recent Events

  • 18 Jan 2024 Adverse events data from a preclinical study released by NeuroBo Pharmaceuticals
  • 14 Sep 2023 Phase-II clinical trials in Non-alcoholic steatohepatitis in USA (PO) (NCT06054815)
  • 02 May 2023 NeuroBo Pharmaceuticals plans a phase IIa trial for Non-alcoholic steatohepatitis (PO) and Type 2 diabetes mellitus in Q3 of 2023
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top